Highlights of This Issue 2593

SPECIAL FEATURES

CCR Translations

2595 Oncolytic Virotherapy Needs Trials, Not Access Programs
Kevin J. Harrington
See article, p. 2734

Molecular Pathways

2598 Molecular Pathways: Tumor-Derived Microvesicles and Their Interactions with Immune Cells In Vivo
Ferdinando Pucci and Mikael J. Pittet

CCR Focus

2606 PFS: The Endpoint We Love and Love to Hate
Susan E. Bates

2607 Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
Ronald L. Korn and John J. Crowley

2613 Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials
Rajeshwari Sridhara, Sumithra J. Mandrekar, and Lori E. Dodd

2621 The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival
Daniel Carl Sullivan, Lawrence H. Schwartz, and Binsheng Zhao

2629 The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
Liza C. Villaruz and Mark A. Socinski

2637 Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials
Jenny J. Zhang, Lijun Zhang, Huanyu Chen, Anthony J. Muro, Lori E. Dodd, Richard Pazdur, and Rajeshwari Sridhara

2646 Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial
Mary W. Redman, Bryan H. Goldman, Michael LeBlanc, Anne Schott, and Laurence H. Baker

HUMAN CANCER BIOLOGY

2657 Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
Sucharita Balasubramaniam, Clay E.S. Comstock, Adam Ertel, Kwang Won Jeong, Michael R. Stallcup, Sankar Addya, Peter A. McCue, William F. Ostrander Jr, Michael A. Augello, and Karen E. Knudsen

2668 Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

CANCER THERAPY: PRECLINICAL

2677 Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
Stela Álvarez-Fernández, Maria Jesús Ortiz-Ruiz, Tracy Parrott, Sara Zaknoen, Enrique M. Oxio, Jesús San Miguel, Francis J. Burrows, Azucena Esparris-Ogando, and Atanasio Pandiella

2688 Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAF<sup>600E</sup> Colorectal Cancer
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2710</td>
</tr>
<tr>
<td>2723</td>
</tr>
<tr>
<td>2734</td>
</tr>
<tr>
<td>2755</td>
</tr>
<tr>
<td>2775</td>
</tr>
</tbody>
</table>
| 2777 | Correction: Chromosome 5q Loss in Colorectal Flat Adenomas
ABOUT THE COVER

This image is taken from a bone metastasis in a patient with stage IV relapsed invasive CDH1 mutated lobular carcinoma of the breast. The tumor was negative for ERBB2 (HER2) amplification (FISH). The targeted next generation sequencing assay used in this study found an ERBB2-GRB7 putative gene fusion that has not been previously reported. The fusion retains the kinase domain of ERBB2 (uniprot.org) which suggests that it could result in ERBB2 activation. The 17q12-21 amplicon which includes both ERBB2 and GRB7 is frequently amplified in breast cancer and preclinical studies suggest that it may be a recombination hotspot. An expression screening study has reported that GRB7 can function as an ERBB2-dependent oncogene. GRB7 encodes an adaptor protein that interacts with ERBB2 and has been shown in a preclinical study to enhance its transformative capacity and increase ERBB2 phosphorylation in fibroblasts. For details, see the article by Ross and colleagues on page 2668 of this issue.

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org
Clinical Cancer Research

19 (10)


Updated version  Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/10

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.